Rohto Pharmaceutical (4527.T) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

4527.T · Stock Price

JPY 2,367-93 (-3.76%)

Market Cap: $3.4B

Historical price data

Market Cap: $3.4BPipeline: 8 drugsPatents: 20Founded: 1899Employees: 3,000-5,000HQ: Osaka, Japan

Overview

Founded in 1899, Rohto Pharmaceutical has built a dominant global franchise in consumer healthcare, particularly in eye drops and skincare, generating stable revenues and deep consumer trust. The company's core strategy involves using this financial strength to fund a strategic pivot into biopharmaceutical R&D, with a focused pipeline in ophthalmology, dermatology, and metabolic diseases. Its achievements include a formidable OTC brand portfolio, international distribution, and the advancement of several drug candidates, positioning it for long-term growth beyond its traditional market.

OphthalmologyDermatologyImmunologyMetabolic Disease

Technology Platform

Rohto's core platform is its deep expertise in pharmaceutical formulation and targeted drug delivery systems, particularly for ophthalmic and topical applications, honed over decades of developing market-leading OTC products.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
Mesenchymal stem cell + Placebo	SARS-CoV-2 Infection( COVID-19 )	Phase 2
Mesenchymal stem cell + Placebo	Ischemic Heart Disease	Phase 2
Mesenchymal stem cell	Decompensated Liver Cirrhosis	Phase 1/2
UDI-001	Cerebral Palsy	Phase 1/2
ADR-002K administration	D017202	Phase 1

Opportunities

Rohto has multiple near-term catalysts from its Phase 3/2 pipeline in high-value areas like Sjögren's and NASH.

Its strong balance sheet and OTC cash flow provide unique flexibility to in-license additional assets or make strategic acquisitions to accelerate growth.

Risk Factors

Clinical failure of key late-stage assets like Dazodalibep poses the greatest risk.

The company also faces the challenge of building a commercial infrastructure for specialty pharmaceuticals and depends on partners for its most advanced pipeline candidates.

Competitive Landscape

In OTC, Rohto competes with global giants like J&J and Bayer on brand strength. In biopharma, it faces large-cap pharma and biotechs in immunology and NASH, competing through focused development and formulation expertise rather than sheer scale.

More companies in Japan →